CASI Pharmaceuticals CASI Stock
CASI Pharmaceuticals Price Chart
CASI Pharmaceuticals CASI Financial and Trading Overview
CASI Pharmaceuticals stock price | 2.13 USD |
Previous Close | 2.09 USD |
Open | 2.09 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 900 |
Day's Range | 1.99 - 2.15 USD |
52 Week Range | 1.45 - 4.86 USD |
Volume | 42.01K USD |
Avg. Volume | 39.65K USD |
Market Cap | 27.44M USD |
Beta (5Y Monthly) | 0.438028 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.23 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10 USD |
CASI Valuation Measures
Enterprise Value | 6.23M USD |
Trailing P/E | N/A |
Forward P/E | -4.577778 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.64734596 |
Price/Book (mrq) | 0.694304 |
Enterprise Value/Revenue | 0.147 |
Enterprise Value/EBITDA | -0.261 |
Trading Information
CASI Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 0.438028 |
52-Week Change | -30.87% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.86 USD |
52 Week Low | 1.45 USD |
50-Day Moving Average | 2.7 USD |
200-Day Moving Average | 2.35 USD |
CASI Share Statistics
Avg. Volume (3 month) | 39.65K USD |
Avg. Daily Volume (10-Days) | 31.28K USD |
Shares Outstanding | 13.32M |
Float | 7.26M |
Short Ratio | 13.3 |
% Held by Insiders | 37.45% |
% Held by Institutions | 12.90% |
Shares Short | 240.54K |
Short % of Float | 2.13% |
Short % of Shares Outstanding | 1.80% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -90.64% |
Operating Margin (ttm) | -62.44% |
Gross Margin | 63.56% |
EBITDA Margin | -56.32% |
Management Effectiveness
Return on Assets (ttm) | -15.18% |
Return on Equity (ttm) | -46.83% |
Income Statement
Revenue (ttm) | 42.39M USD |
Revenue Per Share (ttm) | 3.13 USD |
Quarterly Revenue Growth (yoy) | -7.90% |
Gross Profit (ttm) | N/A |
EBITDA | -23878500 USD |
Net Income Avi to Common (ttm) | -38427000 USD |
Diluted EPS (ttm) | -3.01 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 44.29M USD |
Total Cash Per Share (mrq) | 3.32 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 4.744 |
Book Value Per Share (mrq) | 2.967 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of CASI Pharmaceuticals
Country | United States |
State | N/A |
City | Beijing |
Address | 1701-1702, China Central Office Tower 1 |
ZIP | 100025 |
Phone | 86 10 6508 6063 |
Website | https://www.casipharmaceuticals.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 224 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Q&A For CASI Pharmaceuticals Stock
What is a current CASI stock price?
CASI Pharmaceuticals CASI stock price today per share is 2.13 USD.
How to purchase CASI Pharmaceuticals stock?
You can buy CASI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CASI Pharmaceuticals?
The stock symbol or ticker of CASI Pharmaceuticals is CASI.
Which industry does the CASI Pharmaceuticals company belong to?
The CASI Pharmaceuticals industry is Biotechnology.
How many shares does CASI Pharmaceuticals have in circulation?
The max supply of CASI Pharmaceuticals shares is 15.49M.
What is CASI Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
CASI Pharmaceuticals PE Ratio is now.
What was CASI Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
CASI Pharmaceuticals EPS is -2.23 USD over the trailing 12 months.
Which sector does the CASI Pharmaceuticals company belong to?
The CASI Pharmaceuticals sector is Healthcare.
CASI Pharmaceuticals CASI included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
NASDAQ Capital Market Composite RCMP | 96.46 USD — |
-4.76
|
— — | 95.94 USD — | 97.68 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}